Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: A randomized trial

Journal of Interventional Cardiology

Volumn 24, Issue 2, 2011, Pages 105-111

  Iversen, Allan ^a   Abildgaard, Ulrik ^a   Galloe, Anders ^a   Hansen, Peter R ^a   Galatius, Soren ^a   Madsen, Jan K ^a   Engstroem, Thomas ^a   Pedersen, Sune ^a   Jensen, Kurt S ^a   Jensen, Jan S ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CORONARY VESSELS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; TREATMENT OUTCOME;

EID: 79953794038     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2010.00616.x     Document Type: Article

References (43)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevationmyocardial infarction - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:588-636.
2. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20. (Pubitemid 36050955)
4. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-742. (Pubitemid 37010777)
5. Van de WF, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
6. The EPIC Investigators use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
7. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at sixmonths. The EPIC Investigators. Lancet 1994;343:881-886. (Pubitemid 24113631)
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
9. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-2024.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
11. Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non- ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: Results of the ISAR-REACT 2 randomized trial. Eur Heart J 2008;29:455-461. (Pubitemid 351264175)
12. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
13. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
14. Bailey SR, O'Leary E, Chilton R. Angioscopic evaluation of site-specific administration of ReoPro. Cathet Cardiovasc Diagn 1997;42:181-184.
15. Bartorelli AL, Trabattoni D, Galli S, et al. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 1999;48:211-213. (Pubitemid 29458325)
16. Barsness GW, Buller C, Ohman EM, et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. Am Heart J 2000;139:824-829. (Pubitemid 30305404)
17. Kandzari DE, Behar VS, Sketch MH, et al. Extensive thrombus prior to elective percutaneous coronary intervention. J Invasive Cardiol 2001;13:538-542.
18. Lee CH, Ho KT, Tan HC. Instant dissolution of intracoronary thrombus by abciximab. Int J Cardiol 2005;104:102-103.
19. Carey BC, Blankenship JC. A sequential approach to the management of a massive intracoronary thrombus in ST elevation myocardial infarction: A case report. Angiology 2007;58:106-111.
20. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005;105:250-255. (Pubitemid 41605072)
21. Wöhrle J, Nusser T, Mayer C, et al. Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. Eurointervention 2007;3:465-469.
22. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004;61:31-34. (Pubitemid 38036787)
23. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107:1840-1843. (Pubitemid 36444121)
24. Galache Osuna JG, Sanchez-Rubio J, Calvo I, et al. Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial]. Rev Esp Cardiol 2006;59:567-574. (Pubitemid 44203201)
25. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004;62:186-192. (Pubitemid 38788695)
26. Romagnoli E, Burzotta F, Trani C, et al. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007;23:57-63.
27. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57.
28. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463. (Pubitemid 41821197)
29. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351. (Pubitemid 46685903)
30. Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44:2133-2136. (Pubitemid 39576031)
31. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA2006;295:1531-1538.
32. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 2009;119:1933-1940.
33. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-231. (Pubitemid 29088046)
34. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004;44:316-323. (Pubitemid 38950589)
35. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764. (Pubitemid 24320922)
36. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-1688. (Pubitemid 28211416)
37. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 2002;87:1020-1025. (Pubitemid 34624885)
38. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001;21:142-148. (Pubitemid 32061939)
39. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-874. (Pubitemid 26349192)
40. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A systematic review and meta-analysis. J Invasive Cardiol 2010;22:278-282.
41. Deibele AJ, Kirtane AJ, Pinto DS, et al. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 2006;22:47-50. (Pubitemid 43923001)
42. Capodanno D, Prati F, Pawlowsky T, et al. ClearWayRXsystem to reduce intracoronary thrombus in patients with acute coronary sydnromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): Study rationale and design. J Cardiovasc Med 2010;11:130-136.
43. Thiele H, Wöhrle J, Neuhaus P, et al. Intracoronay compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010;159:547-554.